Bison Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bison Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,230	Closed	-$235K	–	425
2023 Q4	$235K	Sell	1,230 -1,323	-52%	-$225K	0.04%	354
2023 Q3	$452K	Sell	2,553 -2,157	-46%	-$412K	0.09%	232
2023 Q2	$895K	Buy	4,710 +154	+3%	+$30.5K	0.17%	135
2023 Q1	$939K	Sell	4,556 -20	-0.4%	-$4.2K	0.29%	103
2022 Q4	$1.03M	Sell	4,576 -1,889	-29%	-$403K	0.33%	97
2022 Q3	$1.29M	Buy	+6,465	New	+$1.23M	0.51%	61

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bison Wealth's ALNY Position: Q1 2024 in Review

Bison Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 1,230 shares — an estimated $235K sold.

Bison Wealth first reported a position in ALNY in Q3 2022 and held it in 6 quarters. The position peaked at $1.29M in Q3 2022. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

Bison Wealth reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Bison Wealth sold 1,230 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $235K.
Bison Wealth first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 6 quarters.
Bison Wealth's Alnylam Pharmaceuticals position peaked at $1.29M in Q3 2022.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Bison Wealth's 13F filing for Q1 2024, filed 10 May 2024.